| アブストラクト | BACKGROUND: As prostaglandin medications, crucial in glaucoma treatment, become more widely used, their local adverse events are increasingly observed. OBJECTIVES: To evaluate the common adverse events of four clinically commonly used prostaglandin F (FP) receptor agonists in the treatment of glaucoma in the Food and Drug Administration Adverse Event Reporting System (FAERS) database. DESIGN: We screened and analyzed the generic and brand names of latanoprost, bimatoprost, travoprost, and tafluprost in the FAERS database and summarized and cleaned the baseline information of subjects receiving the above-mentioned drugs. METHODS: Perform descriptive statistical analysis on the baseline information of subjects using the drugs. Conduct disproportionality analysis of drug-related adverse events. The criteria for positive signals of adverse events are established by simultaneously meeting the thresholds set by four methods: the ratio of reported odds, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker. Additionally, assess the cumulative risk curves for drug-induced time of the aforementioned drugs and use one-way ANOVA to compare differences in drug-induced time across different groups. RESULTS: The study included 1567 latanoprost, 1517 bimatoprost, 696 travoprost, and 82 tafluprost subjects. Adverse events mainly affected eye disorders, with significant issues in iris hyperpigmentation, ocular pemphigoid, corneal endothelial cell loss, periorbital fat atrophy, corneal irritation, eyelash growth, and ocular hyperemia. The time to onset varied among drugs, with latanoprost showing the longest (mean days = 344.37) and bimatoprost the shortest duration (mean days = 155.65; p < 0.001). CONCLUSION: Although signal detection analysis based on the FAERS database cannot establish a definitive causal relationship, our study found that FP receptor agonists used in glaucoma can cause various adverse events. Assessing their clinical suitability and potential side effects is crucial for providing personalized treatment and ensuring medication safety. |
|---|
| ジャーナル名 | Therapeutic advances in drug safety |
|---|
| Pubmed追加日 | 2024/10/21 |
|---|
| 投稿者 | Wu, Shi-Nan; Huang, Caihong; Wang, Yu-Qian; Li, Xiang; Zhang, Si-Qi; Chen, Xiao-Dong; Qin, Dan-Yi; Zhu, Linfangzi; Wen, Jia-Yi; Luo, Na-Chuan; Hu, Jiaoyue; Liu, Zuguo |
|---|
| 組織名 | Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory;of Ophthalmology and Visual Science, Fujian Engineering and Research Center of;Eye Regenerative Medicine, Eye Institute of Xiamen University, School of;Medicine, Xiamen University, Xiamen, Fujian, China.;Department of Oncology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian,;China.;Department of Ophthalmology, The First Affiliated Hospital of Nanchang;University, Jiangxi Branch of the National Clinical Research Center for Ocular;Disease, Nanchang, Jiangxi, China.;State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen;University, Guangzhou, Guangdong, China.;Medicine, Xiamen University, 401 Chengyi Build, Xiang-an Campus of Xiamen;University, South Xiang-an Road, Xiamen, Fujian 361005, China.;Department of Ophthalmology, Xiang'an Hospital of Xiamen University, Xiamen,;Fujian, China.;Department of Ophthalmology, Xiang'an Hospital of Xiamen University; Xiamen,;Department of Ophthalmology, The First Affiliated Hospital of University of South;China, Hengyang, Hunan, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39429679/ |
|---|
